|Bid||134.27 x 100|
|Ask||134.29 x 200|
|Day's Range||133.86 - 134.97|
|52 Week Range||109.32 - 137.08|
|PE Ratio (TTM)||22.57|
|Earnings Date||Oct 17, 2017|
|Dividend & Yield||3.36 (2.52%)|
|1y Target Est||137.05|
India has capped prices of orthopaedic knee implants, in the country's latest move to bring down prices of medical devices. The introduction of price controls marks the latest step by Prime Minister Narendra Modi's government to make drugs and medical devices more affordable. India's drug pricing authority said on Wednesday that orthopaedic implants in India had unjustified, unreasonable and irrationally high trade margins, leading to exorbitant pricing.
Giving credit where credit is due, I do think Valeant Pharmaceuticals Intl Inc (NYSE:VRX) stock looks stronger than it did just a couple of quarters ago. VRX stock has still declined 1.5% so far this year, but the narrative surrounding the company has certainly changed. On the Q2 conference call, Valeant management made a big deal of the fact that 73% of Q2 revenue came from Bausch & Lomb and the Salix business.
Donald Trump has ramped up his rhetorical assault on US business leaders, labelling corporate critics of his response to white nationalist violence in Virginia as "grandstanders" and accusing ...